Company news
Pulse Biosciences, Inc (NASDAQ:PLSE) news
Every Pulse Biosciences, Inc press release and news update in one place — announcements, filings coverage, and company updates for investors.
Press releases & updates
Pulse Biosciences to Present at Canaccord Genuity’s 46th Annual Growth Conference
July 30, 2026
Pulse Biosciences Surpasses Enrollment Midpoint in NANOPULSE-AF IDE Pivotal Study
July 29, 2026
Pulse Biosciences Schedules Second Quarter 2026 Financial Results Conference Call for August 6, 2026
July 21, 2026
Pulse Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(4)
July 16, 2026
Pulse Biosciences to Present at the Goldman Sachs 47th Annual Global Healthcare Conference 2026
May 27, 2026
ATM Equity Purchases by Pulse Biosciences’ Co-Chairmen Total Approximately $13.3 Million
May 12, 2026
Pulse Biosciences to Present at the BofA Securities 2026 Healthcare Conference
May 8, 2026
Turbett Surgical Appoints Kevin Danahy as President and Chief Executive Officer to Lead Growth Phase
May 6, 2026
Pulse Biosciences Reports Business Updates and First Quarter 2026 Financial Results
May 4, 2026
Pulse Biosciences Presents Positive Outcomes in Late-Breaking Updated Data from nPulse™ Cardiac Catheter System at Heart Rhythm 2026
April 25, 2026
Pulse Biosciences’ nPulse™ Technology to be Featured at the Heart Rhythm Society 2026 Annual Meeting
April 20, 2026
Pulse Biosciences to Host Analyst Event on April 25, 2026
April 17, 2026
Pulse Biosciences Strengthens Executive Leadership Team
April 9, 2026
Pulse Biosciences Enrolls First Patients in NANOPULSE-AF IDE Pivotal Clinical Study Evaluating nPulse™ Cardiac Catheter System for Atrial...
April 7, 2026
Pulse Biosciences to Present at the 25th Annual Needham Virtual Healthcare Conference
April 2, 2026
Pulse Biosciences Announces Strategic Alignment to Accelerate Cardiac Catheter Program Following Exceptional Long-Term AFib Clinical Data
March 17, 2026
Pulse Biosciences, Inc. Announces First Enrollments in Feasibility Study for the Treatment of Malignant Thyroid Tumors with nPulse™ Techn...
March 12, 2026
Pulse Biosciences Announces Clinical Data From nPulse™ Vybrance™ System First-In-Human Clinical Durability Study of Benign Thyroid Nodule...
March 9, 2026
Pulse Biosciences to Present at the Oppenheimer 36th Annual Healthcare MedTech & Services Conference
March 5, 2026
Pulse Biosciences’ nPulse™ Vybrance™ System to be Featured in Multiple Presentations at the North American Society for Interventional Thy...
March 4, 2026
Pulse Biosciences to Present at the 46th Annual TD Cowen Healthcare Conference
February 20, 2026
Pulse Biosciences Reports Business Updates and Fourth Quarter & Full Year 2025 Financial Results
February 19, 2026
Pulse Biosciences Presents Late-Breaking Data from nPulse™ Cardiac Catheter System First-In-Human Feasibility Study at the AF Symposium
February 5, 2026
Pulse Biosciences Schedules Fourth Quarter & Full Year 2025 Financial Results Conference Call for February 19, 2026
February 4, 2026
Pulse Biosciences’ nPulse™ Cardiac Catheter to Be Featured in Multiple Presentations at the AF Symposium
February 3, 2026
Pulse Biosciences, Inc. Appoints Maria Sainz to its Board of Directors
January 9, 2026
Pulse Biosciences Selected to Present Late-Breaking Data from the nPulse Cardiac Catheter Study at the AF Symposium
January 6, 2026
Pulse Biosciences to Present at the 44th Annual J.P. Morgan Healthcare Conference
December 29, 2025
Pulse Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
December 19, 2025
Pulse Biosciences Announces FDA IDE Approval to Initiate its nPulse Cardiac Catheter Ablation System Study for the Treatment of Atrial Fi...
December 18, 2025
Pulse Biosciences, Inc. Announces Initiation of Research Collaboration for the Treatment of Benign and Malignant Thyroid Tumors with nPul...
December 9, 2025
Pulse Biosciences, Inc. Announces Participation in Upcoming Investor Conferences
November 6, 2025
Pulse Biosciences Reports Business Updates and Third Quarter 2025 Financial Results
November 5, 2025
Pulse Biosciences Announces First Enrollment in the NANOCLAMP AF Study
October 24, 2025
Pulse Biosciences Schedules Third Quarter 2025 Business Updates and Financial Results Conference Call for November 5, 2025
October 22, 2025
Pulse Biosciences Announces Presentation of Late-Breaking Data From the nPulse™ Cardiac Surgical System First-in-Human Feasibility Study ...
October 10, 2025
Pulse Biosciences Announces Clinical Data Highlighting its nPulse™ Cardiac Surgical System to be Presented at the 39th European Associati...
October 7, 2025
Pulse Biosciences’ nPulse™ Technology to be Featured at the American Thyroid Association 2025 Annual Meeting
September 10, 2025
Pulse Biosciences Announces FDA IDE Approval to Initiate its nsPFA Cardiac Surgery System Study for the Treatment of Atrial Fibrillation
September 8, 2025
Pulse Biosciences Announces First Successful Procedures in PRECISE Benign Thyroid Nodule (BTN) Study
September 2, 2025
Pulse Biosciences Announces Publication of First-In-Human Data for Treatment of Benign Thyroid Nodules in the Journal Thyroid
August 26, 2025
Pulse Biosciences Reports Business Updates and Second Quarter 2025 Financial Results
August 12, 2025
Pulse Biosciences To Present at the 45th Canaccord Genuity Annual Growth Conference
August 1, 2025
Pulse Biosciences Schedules Second Quarter 2025 Business Updates and Financial Results Conference Call for August 12, 2025
July 29, 2025
Pulse Biosciences Reports Business Updates and First Quarter 2025 Financial Results
May 8, 2025
Pulse Biosciences To Present at the BofA Securities 2025 Health Care Conference
May 6, 2025
Pulse Biosciences’ Nanosecond PFA Technology to be Featured at The American Association for Thoracic Surgery 2025 Annual Meeting
May 1, 2025
Pulse Biosciences Schedules First Quarter 2025 Financial Results Conference Call for May 8, 2025
April 24, 2025
Pulse Biosciences’ Nanosecond PFA Technology to be Featured at The Heart Rhythm Society 2025 Annual Meeting
April 23, 2025
Pulse Biosciences Reports Business Updates and Fourth Quarter & Full Year 2024 Financial Results
March 27, 2025